相关实验视频

Updated: Jul 11, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

在成年急性髓性白血病的Venetoclax

Mengci Hu¹, Wenzhe Li², Youshan Zhang¹

¹Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|November 5, 2023

概括

维尼托克拉克斯有效向B细胞淋巴瘤-2 (BCL-2) 治疗急性髓性白血病 (AML). 需要进一步的研究来优化其使用,并确定患者反应的生物标志物.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

急性髓性白血病 (AML) 往往呈现出不良预后,特别是在不能容忍密集化疗的患者中.
B细胞淋巴瘤-2 (BCL-2) 是癌细胞生存中的关键蛋白质,使其成为新型治疗的目标.
作为BCL-2抑制剂的Venetoclax在AML的临床前和临床环境中表现有前途.

研究的目的:

审查目前基于venetoclax的AML治疗的现状.
讨论venetoclax作为单一治疗和组合治疗方案的疗效.
突出未来研究领域,包括最佳剂量,测序和生物标志物识别.

主要方法:

审查涉及AML细胞系和异种移植模型的临床前研究.
在AML患者中分析venetoclax的临床试验数据.
综合了有关venetoclax机制和临床结果的现有文献.

主要成果:

威尼托克拉克斯在AML中显示出显著的抗白血病活性.
在预后不利的患者和不适合强化化疗的患者中有效.
显示作为单一药物和组合疗法的有效性.

结论:

威尼托克拉克斯为特定的AML患者群体提供了一种革命性的治疗选择.
最佳的venetoclax剂量,测序和组合策略需要进一步调查.
生物标志物的发现对于预测AML治疗反应和对venetoclax的耐药性至关重要.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.组合疗法是一种组合疗法.威尼托克拉克斯 (Venetoclax) 是一个属于威尼托克拉克斯的地区.

更多相关视频

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...